CONBA(SH:600572)2023-04-18 16:00Financial Performance - Net profit for Q1 2023 reached ¥324,873,847.25, compared to ¥134,649,996.91 in Q1 2022, reflecting a significant increase of approximately 141.1%[9] - Operating profit improved to ¥414,273,086.25 from ¥185,283,608.06, marking an increase of around 123.0% year-over-year[9] - The company achieved operating revenue of CNY 2.13 billion in Q1 2023, a year-on-year increase of 25.27%[16] - Net profit attributable to shareholders reached CNY 284.21 million, representing a significant growth of 175.17% compared to the same period last year[16] - The total comprehensive income for the period was 324,873,847.25 RMB, compared to 134,607,490.12 RMB in the previous year, representing a year-over-year increase of about 141%[45] - The total comprehensive income for Q1 2023 was CNY 45,151,309.05, compared to CNY 29,918,826.58 in Q1 2022, representing an increase of approximately 51.5%[58] Revenue and Costs - Total revenue for Q1 2023 reached CNY 2,130,542,570.91, a 25.4% increase from CNY 1,700,711,224.91 in Q1 2022[39] - Total operating costs for Q1 2023 were CNY 1,764,663,628.34, up from CNY 1,434,275,969.50 in Q1 2022, reflecting a 23.0% increase[39] - The company’s core business in traditional Chinese medicine generated revenue of CNY 1.44 billion, a 41% increase, accounting for 67.78% of total revenue[21] - Self-care product revenue reached CNY 1.11 billion, growing by 52.33%, with over-the-counter drugs contributing CNY 967 million, a 55.6% increase[22] Assets and Liabilities - Total assets rose to ¥11,773,272,870.30, up from ¥10,929,964,949.51, indicating an increase of about 7.7%[6] - Total liabilities increased to ¥4,174,378,498.32 from ¥3,605,940,336.82, which is an increase of approximately 15.8%[6] - The total equity attributable to shareholders rose to ¥7,182,747,554.47 from ¥6,913,851,405.56, reflecting an increase of about 3.9%[6] - Total assets increased to CNY 9,251,305,587.28 as of March 31, 2023, up from CNY 8,248,072,073.79 as of December 31, 2022, representing a growth of approximately 12.2%[50] - Total liabilities increased to CNY 2,906,883,910.20 from CNY 1,948,801,705.76, representing a growth of approximately 49.0%[52] Cash Flow - The cash flow from operating activities was CNY 82.90 million, reflecting a 59.24% increase compared to the previous year[16] - Net cash flow from operating activities for Q1 2023 was CNY 82,897,274.21, compared to CNY 52,059,158.79 in Q1 2022, indicating a 59.2% increase[38] - Cash inflow from operating activities totaled CNY 151,982,783.64, up from CNY 127,528,479.96 in the same period last year, indicating a growth of about 19.2%[58] - The net cash flow from operating activities was negative at CNY -26,094,943.93, an improvement from CNY -39,751,238.62 in Q1 2022[58] - Cash inflow from financing activities reached CNY 1,330,690,759.16, an increase from CNY 1,221,077,961.93 in Q1 2022, marking a growth of about 9.0%[60] - The net cash flow from financing activities was CNY 895,584,009.12, compared to CNY 751,339,383.65 in the same quarter last year, indicating an increase of approximately 19.2%[60] Investments and Acquisitions - The company completed the acquisition of 100% equity in Zhejiang Autokang Pharmaceutical Technology Co., Ltd. and 51% equity in Zhejiang Traditional Chinese Medicine University Chinese Herbal Medicine Co., Ltd. in 2022[20] - The company plans to publicly transfer 7.84% equity in Jiangxi Zhenzhiming Pharmaceutical Co., with a minimum transfer price set at CNY 290,000,006 based on a valuation of CNY 3.7 billion[34] - The company’s cash outflow for investing activities was CNY 539,147,115.12, significantly higher than CNY 164,111,873.91 in the previous year, indicating a strategic increase in investments[58] Shareholder Information - The total number of common shareholders at the end of the reporting period was 86,593[31] - Zhejiang Zhongyi Health Industry Group Co., Ltd. holds 20.85% of the shares, making it the largest shareholder[31] - The company has subscribed to 48,899,755 shares of Zhejiang Yingtai Group Co., Ltd. through a private placement[34]